Change in Novel Filtration Markers and Risk of ESRD
Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end po...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Rebholz, Casey M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested - 2013, AJKD : official journal of the National Kidney Foundation, Philadelphia, Pa |
|---|---|
| Übergeordnetes Werk: |
volume:66 ; year:2015 ; number:1 ; pages:47-54 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1053/j.ajkd.2014.11.009 |
|---|
| Katalog-ID: |
ELV023465492 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023465492 | ||
| 003 | DE-627 | ||
| 005 | 20230623170543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2014.11.009 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015008000004.pica |
| 035 | |a (DE-627)ELV023465492 | ||
| 035 | |a (ELSEVIER)S0272-6386(14)01445-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DNB |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 530 |q VZ |
| 084 | |a 52.56 |2 bkl | ||
| 100 | 1 | |a Rebholz, Casey M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Change in Novel Filtration Markers and Risk of ESRD |
| 264 | 1 | |c 2015 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. | ||
| 650 | 7 | |a β2-Microglobulin (B2M) |2 Elsevier | |
| 650 | 7 | |a filtration marker |2 Elsevier | |
| 650 | 7 | |a cystatin C |2 Elsevier | |
| 650 | 7 | |a creatinine |2 Elsevier | |
| 650 | 7 | |a kidney disease outcome |2 Elsevier | |
| 650 | 7 | |a end-stage renal disease (ESRD) |2 Elsevier | |
| 650 | 7 | |a disease progression |2 Elsevier | |
| 650 | 7 | |a surrogate endpoint |2 Elsevier | |
| 650 | 7 | |a chronic kidney disease (CKD) |2 Elsevier | |
| 700 | 1 | |a Grams, Morgan E. |4 oth | |
| 700 | 1 | |a Matsushita, Kunihiro |4 oth | |
| 700 | 1 | |a Selvin, Elizabeth |4 oth | |
| 700 | 1 | |a Coresh, Josef |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Saunders |t The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |d 2013 |d AJKD : official journal of the National Kidney Foundation |g Philadelphia, Pa |w (DE-627)ELV011405082 |
| 773 | 1 | 8 | |g volume:66 |g year:2015 |g number:1 |g pages:47-54 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1053/j.ajkd.2014.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 52.56 |j Regenerative Energieformen |j alternative Energieformen |q VZ |
| 951 | |a AR | ||
| 952 | |d 66 |j 2015 |e 1 |h 47-54 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
c m r cm cmr |
|---|---|
| matchkey_str |
rebholzcaseymgramsmorganematsushitakunih:2015----:hnenoeflrtomres |
| hierarchy_sort_str |
2015 |
| bklnumber |
52.56 |
| publishDate |
2015 |
| allfields |
10.1053/j.ajkd.2014.11.009 doi GBVA2015008000004.pica (DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Rebholz, Casey M. verfasserin aut Change in Novel Filtration Markers and Risk of ESRD 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier Grams, Morgan E. oth Matsushita, Kunihiro oth Selvin, Elizabeth oth Coresh, Josef oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:66 year:2015 number:1 pages:47-54 extent:8 https://doi.org/10.1053/j.ajkd.2014.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 66 2015 1 47-54 8 045F 610 |
| spelling |
10.1053/j.ajkd.2014.11.009 doi GBVA2015008000004.pica (DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Rebholz, Casey M. verfasserin aut Change in Novel Filtration Markers and Risk of ESRD 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier Grams, Morgan E. oth Matsushita, Kunihiro oth Selvin, Elizabeth oth Coresh, Josef oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:66 year:2015 number:1 pages:47-54 extent:8 https://doi.org/10.1053/j.ajkd.2014.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 66 2015 1 47-54 8 045F 610 |
| allfields_unstemmed |
10.1053/j.ajkd.2014.11.009 doi GBVA2015008000004.pica (DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Rebholz, Casey M. verfasserin aut Change in Novel Filtration Markers and Risk of ESRD 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier Grams, Morgan E. oth Matsushita, Kunihiro oth Selvin, Elizabeth oth Coresh, Josef oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:66 year:2015 number:1 pages:47-54 extent:8 https://doi.org/10.1053/j.ajkd.2014.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 66 2015 1 47-54 8 045F 610 |
| allfieldsGer |
10.1053/j.ajkd.2014.11.009 doi GBVA2015008000004.pica (DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Rebholz, Casey M. verfasserin aut Change in Novel Filtration Markers and Risk of ESRD 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier Grams, Morgan E. oth Matsushita, Kunihiro oth Selvin, Elizabeth oth Coresh, Josef oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:66 year:2015 number:1 pages:47-54 extent:8 https://doi.org/10.1053/j.ajkd.2014.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 66 2015 1 47-54 8 045F 610 |
| allfieldsSound |
10.1053/j.ajkd.2014.11.009 doi GBVA2015008000004.pica (DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Rebholz, Casey M. verfasserin aut Change in Novel Filtration Markers and Risk of ESRD 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier Grams, Morgan E. oth Matsushita, Kunihiro oth Selvin, Elizabeth oth Coresh, Josef oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:66 year:2015 number:1 pages:47-54 extent:8 https://doi.org/10.1053/j.ajkd.2014.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 66 2015 1 47-54 8 045F 610 |
| language |
English |
| source |
Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:66 year:2015 number:1 pages:47-54 extent:8 |
| sourceStr |
Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:66 year:2015 number:1 pages:47-54 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Regenerative Energieformen alternative Energieformen |
| institution |
findex.gbv.de |
| topic_facet |
β2-Microglobulin (B2M) filtration marker cystatin C creatinine kidney disease outcome end-stage renal disease (ESRD) disease progression surrogate endpoint chronic kidney disease (CKD) |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| authorswithroles_txt_mv |
Rebholz, Casey M. @@aut@@ Grams, Morgan E. @@oth@@ Matsushita, Kunihiro @@oth@@ Selvin, Elizabeth @@oth@@ Coresh, Josef @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011405082 |
| dewey-sort |
3610 |
| id |
ELV023465492 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023465492</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623170543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2014.11.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015008000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023465492</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(14)01445-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rebholz, Casey M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Change in Novel Filtration Markers and Risk of ESRD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">β2-Microglobulin (B2M)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">filtration marker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cystatin C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">creatinine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">kidney disease outcome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">disease progression</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">surrogate endpoint</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">chronic kidney disease (CKD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grams, Morgan E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsushita, Kunihiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Selvin, Elizabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Coresh, Josef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:47-54</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2014.11.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">47-54</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Rebholz, Casey M. |
| spellingShingle |
Rebholz, Casey M. ddc 610 ddc 530 bkl 52.56 Elsevier β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Change in Novel Filtration Markers and Risk of ESRD |
| authorStr |
Rebholz, Casey M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011405082 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DNB 610 VZ 530 VZ 52.56 bkl Change in Novel Filtration Markers and Risk of ESRD β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) Elsevier |
| topic |
ddc 610 ddc 530 bkl 52.56 Elsevier β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) |
| topic_unstemmed |
ddc 610 ddc 530 bkl 52.56 Elsevier β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) |
| topic_browse |
ddc 610 ddc 530 bkl 52.56 Elsevier β2-Microglobulin (B2M) Elsevier filtration marker Elsevier cystatin C Elsevier creatinine Elsevier kidney disease outcome Elsevier end-stage renal disease (ESRD) Elsevier disease progression Elsevier surrogate endpoint Elsevier chronic kidney disease (CKD) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m e g me meg k m km e s es j c jc |
| hierarchy_parent_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| hierarchy_parent_id |
ELV011405082 |
| dewey-tens |
610 - Medicine & health 530 - Physics |
| hierarchy_top_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011405082 |
| title |
Change in Novel Filtration Markers and Risk of ESRD |
| ctrlnum |
(DE-627)ELV023465492 (ELSEVIER)S0272-6386(14)01445-0 |
| title_full |
Change in Novel Filtration Markers and Risk of ESRD |
| author_sort |
Rebholz, Casey M. |
| journal |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| journalStr |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
47 |
| author_browse |
Rebholz, Casey M. |
| container_volume |
66 |
| physical |
8 |
| class |
610 610 DNB 610 VZ 530 VZ 52.56 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Rebholz, Casey M. |
| doi_str_mv |
10.1053/j.ajkd.2014.11.009 |
| dewey-full |
610 530 |
| title_sort |
change in novel filtration markers and risk of esrd |
| title_auth |
Change in Novel Filtration Markers and Risk of ESRD |
| abstract |
Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. |
| abstractGer |
Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. |
| abstract_unstemmed |
Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 |
| container_issue |
1 |
| title_short |
Change in Novel Filtration Markers and Risk of ESRD |
| url |
https://doi.org/10.1053/j.ajkd.2014.11.009 |
| remote_bool |
true |
| author2 |
Grams, Morgan E. Matsushita, Kunihiro Selvin, Elizabeth Coresh, Josef |
| author2Str |
Grams, Morgan E. Matsushita, Kunihiro Selvin, Elizabeth Coresh, Josef |
| ppnlink |
ELV011405082 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1053/j.ajkd.2014.11.009 |
| up_date |
2024-07-06T18:55:47.288Z |
| _version_ |
1803857058635710464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023465492</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623170543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2014.11.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015008000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023465492</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(14)01445-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rebholz, Casey M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Change in Novel Filtration Markers and Risk of ESRD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">β2-Microglobulin (B2M)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">filtration marker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cystatin C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">creatinine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">kidney disease outcome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">disease progression</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">surrogate endpoint</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">chronic kidney disease (CKD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grams, Morgan E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsushita, Kunihiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Selvin, Elizabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Coresh, Josef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:47-54</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2014.11.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">47-54</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4004087 |